Logotype for Dexcom Inc

Dexcom (DXCM) Q4 2020 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dexcom Inc

Q4 2020 earnings summary

4 Nov, 2026

Executive summary

  • FY20 revenue rose 31% to $1.927B; gross margin reached 66%, operating income was $299.5M, and net income was $493.6M, including a material deferred-tax valuation allowance release.

  • Global CGM users exceeded 900,000 by year-end, with record annual new-customer additions; manufacturing capacity doubled in H1 despite pandemic challenges.

Financial highlights

  • Revenue increased $450.7M YoY to $1,926.7M, led by higher disposable sensor volume; pricing pressure from channel strategy and product mix partly offset growth.

  • Gross profit rose 37% to $1,280.1M; gross margin improved to 66% from 63%, driven by revenue growth, product-design improvements and manufacturing efficiencies.

  • Operating income increased to $299.5M from $142.3M; R&D rose 32% to $359.9M and SG&A rose 20% to $620.7M.

  • Net income was $493.6M vs. $101.1M; diluted EPS was $5.06 vs. $1.10, with results boosted by the deferred-tax valuation allowance release.

  • Cash, cash equivalents and short-term marketable securities totaled $2.71B at year-end, up $1.18B YoY.

Outlook and guidance

  • Management expects cash, marketable securities, operating cash flows and available credit to cover anticipated operating and capital needs for at least the next 12 months.

  • 2021 priorities include extending global CGM access and advancing G7; G7 is a one-piece disposable wearable with a 60% size reduction vs. G6.

  • Continued R&D investment is planned to develop next-generation products and services; pivotal G7 clinical work was completed, while COVID-related delays and supply disruption remain uncertainties.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dexcom